4C Medical Technologies Completes $35 Million Series C Financing and Appoints Saravana Kumar as President and CEO

MINNEAPOLIS, March 31, 2022 /PRNewswire/ — 4C Medical Technologies, Inc. (“4C Professional medical” or the “Firm”), a privately-held medical technological know-how organization concentrated on the improvement of minimally invasive therapies for structural heart ailment, declared that it has finished a $35.4 million Sequence C Desired Inventory financing.  The Collection C round was led by MicroPort CardioFlow Medtech Company (HKEX:2160).

As component of the closing, 4C Health care also announced the appointment of Saravana Kumar, PhD as its President & Main Government Officer.  Dr. Kumar has served as the Company’s interim President and CEO because March 2021 soon after obtaining previously served as the Firm’s Vice President of R&D and Operations since November 2017.

“We are pleased to have somebody as focused and goal-oriented as Dr. Kumar major our business to the next progress stage, focusing on the even further enchancement of our transseptal supply system, including the introduction of the up coming era minimal profile method, and continuing medical evidence accumulating for our AltaValve transcatheter mitral valve substitute (TMVR) device,” reported Dr. Jeff Chambers, Founder and Chairman of the Board of 4C Clinical.

“We are grateful for all the curiosity and help we obtained from our traders. The sizeable funds elevated in the Series C spherical furtherhkex emphasizes the importance of continuing to establish our AltaValve® TMVR engineering and spotlight its differentiated layout and potential to increase the treatable affected individual population utilizing our streamlined techniques,” claimed Dr. Kumar. “The money will also permit us to broaden our product or service portfolio with the initiation of our tricuspid plan.”

About 4C Health-related Technologies, Inc.
4C Medical is a professional medical system corporation producing minimally invasive technologies for structural heart ailment, focusing initially on mitral regurgitation (MR) treatment and subsequently on tricuspid regurgitation therapy. Topic to regulatory approvals, the Firm’s AltaValve® would be the 1st MR remedy with atrial-only fixation that is made to lower acknowledged problems linked with present TMVR systems, which depend on placement and fixation within just the native mitral annulus.

 Media Contacts

Saravana Kumar, PhD

President & Chief Government Officer

(612) 968-5236

[email protected]  

Katherine Kumar, PhD, RAC

Senior Govt Vice President

(612) 716-5578

[email protected]

Resource 4C Medical Technologies, Inc.